Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology Feb 28, 2017
Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder Feb 16, 2017
Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD. Dec 12, 2016
Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits at the Radiation Research Society Annual Meeting Oct 20, 2016
Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder Sep 21, 2016
